Summary & Overview
CPT 0519U: SyncView® PainPlus LC–MS/MS Plasma Drug Panel
CPT code 0519U identifies a Proprietary Laboratory Analyses (PLA) test — SyncView® PainPlus from Phenomics Health™ Inc. — that measures plasma concentrations of 110+ drugs used to treat pain, depression, and anxiety using LC–MS/MS. Nationally, the code matters because it represents a high-complexity, manufacturer-specific laboratory service that informs medication management, adherence assessment, and safety monitoring across outpatient and reference laboratory settings. The PLA designation means the code applies only to this single commercial test, which can affect coverage determinations and payer policy development.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical purpose of the test, typical service settings, and the landscape of payer consideration for proprietary laboratory assays. The publication summarizes benchmark topics relevant to stakeholders: coding and billing implications for a PLA code, how this test may be positioned in prior authorization and medical necessity frameworks, and clinical context for interpreting comprehensive plasma drug panels in pain, depression, and anxiety management. Data not available in the input are noted where applicable.
Billing Code Overview
CPT code 0519U is a Proprietary Laboratory Analyses (PLA) code that applies only to the SyncView® PainPlus test from Phenomics Health™ Inc. The test uses liquid chromatography–tandem mass spectrometry (LC–MS/MS) to analyze plasma and measure levels of 110 or more medications commonly used to treat pain, depression, and anxiety, including prescribed, nonprescribed, and illicit substances. Results report the concentration of medications in circulation and indicate whether levels fall within minimally effective ranges.
Service Type: Clinical laboratory test — proprietary plasma drug level panel using LC–MS/MS
Typical Site of Service: Clinical laboratory or reference laboratory, outpatient collection sites, and facilities that send specimens to a reference lab
Clinical & Coding Specifications
Clinical Context
A 48-year-old patient with chronic low back pain and comorbid major depressive disorder is being treated in an outpatient pain management clinic. The patient reports persistent pain despite an evolving regimen of opioid and non-opioid medications and intermittent benzodiazepine use; the clinician needs a comprehensive plasma-level assessment to reconcile self-reported medications, prescriptions in the controlled-substance monitoring program, and possible illicit substances. The clinic orders the proprietary SyncView® PainPlus test (0519U) to quantify circulating concentrations of 110+ analgesic, antidepressant, anxiolytic, and illicit drugs using liquid chromatography–tandem mass spectrometry (LC–MS/MS).
The clinical workflow: the clinician documents the indication (e.g., medication management, suspected nonadherence, suspected diversion, or toxicity risk assessment), places the order for 0519U through the laboratory interface, obtains a timed plasma specimen in the clinic or ambulatory phlebotomy center, and sends the sample to Phenomics Health™ Inc. or the performing laboratory. Results return as a quantitative report indicating which agents and metabolite levels are present and whether concentrations fall within minimally effective ranges. The treating provider integrates the report into medication reconciliation, risk stratification, and treatment planning during follow-up visits. Typical sites of service include outpatient pain clinics, ambulatory surgery centers for preoperative risk assessment, behavioral health clinics involved in medication management, and hospital outpatient phlebotomy centers.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Physician services not otherwise specified | Rare; use only if payer requires explicit standard physician service indicator for lab billing |
26 | Professional component | When reporting only the professional (interpretation) component provided by a physician or qualified practitioner |
52 | Reduced services | When the laboratory performs a reduced or partial version of the test |
53 | Discontinued procedure | If specimen collection or testing was begun but stopped before completion for patient safety or other valid reasons |
62 | Two surgeons | If two distinct practitioners with different specialties jointly interpret or consult on results (rare for PLA) |
78 | Unplanned return to the operating/procedure room by the same physician following initial procedure | Not typical; limited applicability when testing guides urgent return procedures |
80 | Assistant surgeon | Rarely applicable; use only when an assistant surgeon is part of a related procedural episode |
82 | Assistant surgeon (when qualified resident not available) | As above, limited relevance |
QK | Medical direction of two, three, or four technicians/technologists | When the ordering provider medically directs multiple technologists during complex lab processing (if applicable per payer) |
QX | Qualified nonphysician provider with assistant | When a qualified nonphysician assistant performs designated work under supervision |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
207RC0000X | Pain Medicine | Common ordering specialty for comprehensive pain medication monitoring |
2084P0800X | Clinical Pathology | Laboratory directors and pathologists overseeing LC–MS/MS testing and interpretation |
208D00000X | Psychiatry & Neurology (general) | Psychiatrists managing antidepressant/anxiolytic regimens often order comprehensive drug panels |
2083P0200X | Anesthesiology | Anesthesiologists and perioperative medicine clinicians may use results for preoperative risk assessment |
207L00000X | Emergency Medicine | Emergency physicians may order quantitative testing in suspected overdose or toxicity situations |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
G89.2 | Chronic pain, not elsewhere classified | Primary indication for medication monitoring and therapeutic drug-level assessment |
F32.9 | Major depressive disorder, single episode, unspecified | Antidepressant levels and adherence are commonly assessed in combined pain-depression management |
F41.1 | Generalized anxiety disorder | Anxiolytic medication monitoring and detection of concomitant sedative agents |
F11.20 | Opioid dependence, uncomplicated | Monitoring for prescribed opioids, nonprescribed use, or illicit opioids |
T40.2X5A | Poisoning by other opioids, accidental (initial encounter) | Quantitative plasma levels can help assess overdose severity and guide acute management |
Z79.891 | Long term (current) use of opiate analgesic | Documentation supporting ongoing chronic opioid therapy monitoring |
R79.899 | Other specified abnormal findings of blood chemistry | Used when abnormal quantitative drug concentrations are reported and further evaluation is needed |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
80048 | Basic metabolic panel | Often ordered alongside drug testing to assess metabolic status and organ function prior to medication changes |
83655 | Drug testing, qualitative or semiquantitative, multiple drug classes (e.g., immunoassay) | May be used as an initial screen before confirming and quantifying with 0519U |
80307 | Drug test(s), definitive, non-qualitative, multiple drug classes by mass spectrometry, each specimen | Other definitive mass spectrometry drug tests that may be ordered for targeted confirmation; 0519U is a proprietary PLA focused on a broader 110+ panel |
81025 | Urine pregnancy test, qualitative, by instrumented chemistry test system | Commonly ordered in reproductive-age patients prior to medication changes or when toxicology results could affect pregnancy management |
80320 | Drug confirmation, definitive, quantitative, by mass spectrometry for multiple drugs or metabolites | Representative code for quantitative confirmatory testing; used in workflows where plasma quantitation informs dosing and safety decisions |